北京若生智能科技有限公司
Drug Database
AD

AD-201 (AD 201 / AD201)

✓ Approved

Addpharma · 小分子 · 小分子

什么是 AD-201？

AD-201 是一种小分子，由Addpharma研发。该药已获批，用于治疗相关适应症，给药途径：Unknown。

药物档案

商品名AD 201, AD201
公司Addpharma
药物类别小分子
给药途径Unknown
状态Approved
来源： ClinicalTrials.gov, Addpharma

治疗适应症

AD-201 针对 2 个适应症，涉及 2 个治疗领域。

治疗领域疾病/病症分期
Vascular disordersHypertension✓ Approved
Metabolism and nutrition disordersHyperlipidaemia✓ Approved

相关研究文献

PubMedAlzheimer's & dementia (New York, N. Y.)2026-09-10

Understanding dementia in Filipino Americans: risk factors, research gaps, and the role of community-based participatory research.

Reyes Rochelle-Jan Dionisio RD, Guevarra Ariel A, Mamuyac Eugenie E, Posis Alexander Ivan B AIB et al.

Filipino Americans are the third-largest Asian American, Native Hawaiians, and Pacific Islander (AANHPI) group in the United States. Previous studies showed that they have high incident rates of Alzheimer's disease and related dementias (AD/ADRD) compared to other AANHPI groups. However, they are often aggregated into the "Asian" category in AD/ADRD research, masking distinct risk and mitigating factors. To date, no studies have directly explored AD/ADRD factors in Filipino Americans, a community that has unique characteristics from life experiences, immigration, historical and cultural context, and differential burden of genetic risk. In this perspective, we review known AD/ADRD risk and mitigating factors through the lens of the National Institute on Aging's Health Disparities Research Framework, spanning environmental, sociocultural, behavioral, and biological domains, and discuss their relevance to the Filipino American community. By identifying current knowledge gaps and contextualizing AD/ADRD risk and resilience through this framework, we aim to improve understanding of the complex, multifactorial pathways contributing to AD/ADRD outcomes across communities. Lastly, we discuss our experiences and strategies in the recruitment of Filipino Americans for AD/ADRD research studies, outlining challenges, successes, and future directions.

PMID 42719035
阅读全文 →
PubMedAlzheimer's & dementia : the journal of the Alzheimer's Association2026-09-10

TMEM106B is a selective modulator of TDP-43 pathology in Alzheimer's disease.

Reeves Madison M MM, Calliari Anna A, Todd Tiffany W TW, Maroto Cidfuentes Candela C et al.

Co-pathologies - including Lewy body, vascular, and TDP-43 lesions - are common in Alzheimer's disease (AD), contributing to its clinical and pathological heterogeneity. Genetic risk factors may drive mixed pathology presentation, but their influence on the development of specific co-pathologies remains unclear. We evaluated the TMEM106B coding variant rs3173615 and apolipoprotein E (APOE) diplotype (rs429358, rs7412) in post mortem brains from 2604 individuals with a primary neuropathologic diagnosis of AD. Binary logistic regression models linked each genetic modifier with co-pathology risk. The TMEM106B risk variant was significantly enriched in AD cases with transactive response DNA-binding protein 43 kDa (TDP-43) pathology - associating with increased odds of developing AD TDP-43 subtype α - but failed to associate with Lewy body or vascular pathology. In contrast, APOE ε4 associated with increased risk for multiple co-pathologies in AD. We find that genetic factors individually influence AD pathological heterogeneity: TMEM106B selectively modulates TDP-43 co-pathology, while APOE ε4 appears broadly permissive to co-pathology development.

PMID 42720122
阅读全文 →
PubMedJournal of medicinal chemistry2026-09-10

Design and Synthesis of Anemoside B4 Derivatives as Pyruvate Carboxylase-Targeting Therapeutic Agents for Atopic Dermatitis.

Li Heng H, Du Yexin Y, Li Qiurong Q, Zhang Junlei J et al.

Although injectable anemoside B4 (AB4) has therapeutic potential for atopic dermatitis (AD), its clinical use is restricted by safety and pharmacokinetic issues. Therefore, we designed 42 AB4 derivatives, established a preliminary SAR for anti-inflammatory and antiallergic activities, and selected three promising compounds for in vivo evaluation in an AD mouse model, leading to the identification of B4-39 as the lead compound. In a DNCB-induced AD mouse model, topical B4-39 (6.6 mg/kg) was more effective than dexamethasone and free from its side effects, while matching the efficacy of crisaborole at a much lower dose and providing better skin barrier repair. Mechanistically, B4-39 targets pyruvate carboxylase (PC)─a novel therapeutic target in AD─modulating the TCA cycle to suppress dendritic cell activation and concurrently inhibiting NF-κB and NLRP3 inflammasome signaling. Given its enhanced efficacy, steroid-sparing safety, novel PC-targeted action, and favorable topical delivery, B4-39 is a highly promising candidate for AD treatment.

PMID 42720484
阅读全文 →
PubMedFrontiers in medicine2026-09-10

Identifying dendritic cell heterogeneity and potential risk genes in atopic dermatitis: integrative scRNA-seq, bulk RNA-seq analyses and experimental validation.

Huang Chushan C, Chen Pengsheng P, Chen Xiaosong X

Atopic dermatitis (AD) is a chronic inflammatory skin condition marked by immune dysregulation and compromised skin barrier function, with dendritic cells (DCs) playing pivotal roles in its pathogenesis. This study aimed to systematically characterize the heterogeneity of DCs in AD, identify key pathogenic subsets and genes, and elucidate their regulatory mechanisms through advanced methodologies. We conducted integrated single-cell RNA sequencing (scRNA-seq) analyses on both AD lesions and normal skin samples, leading to the identification and functional annotation of distinct DC subtypes. Through deconvolution, pseudotime trajectory, and co-expression network analyses, we screened critical cell populations and candidate genes. Causal associations were assessed using Mendelian randomization and colocalization analyses, while transcription factor activity inference, kNN-DREMI, and motif analysis were employed to explore underlying regulatory mechanisms. Our results revealed five distinct DC subsets, with a notable expansion of CD207+ migratory DCs ( CD 207 m DC ) inADlesi ons, contrasting with the enrichment of IL1B+ DCs in normal skin. CD207_mDCs exhibited enhanced migratory and antigen-presenting capabilities, with CD1B being significantly upregulated and uniquely enriched within this subset. Integrative analyses suggest that CD1B may play a role in AD pathogenesis, potentially regulated by NOTCH1 signaling. These findings underscore the critical involvement of CD207_mDCs in AD progression and highlight CD1B as a promising candidate gene, implicating the NOTCH1-CD1B axis in Th2 polarization and presenting novel therapeutic targets for intervention in AD.

PMID 42718499
阅读全文 →
PubMedAging cell2026-09-10

Novel Therapeutic Insights Into Alzheimer's Disease: Glymphatic System and Meningeal Lymphatic Vessels.

Song Bingbing B, Wang Wei W, Liu Siqi S, Jin Xi X et al.

With the acceleration of global aging, the relationship between Alzheimer's disease (AD) and the glymphatic system (GS) has become a research hotspot in the field of neuroscience in recent years. Traditionally, the central nervous system was thought to lack a lymphatic system; however, research over the past decade has overturned this view. Studies have revealed the existence of GS and meningeal lymphatic vessels (mLVs) in the brain, which clear metabolic waste (such as amyloid-β and tau proteins) through the exchange of cerebrospinal fluid (CSF) and interstitial fluid (ISF). Dysfunction of the GS can lead to abnormal deposition of pathological proteins, which may trigger or exacerbate AD. Currently, the association between the GS and AD treatment mainly focuses on drug development (such as small molecules that promote glymphatic circulation), physical therapies (such as 40 Hz photoacoustic therapy), and surgical interventions (primarily deep cervical lymphatic-vein anastomosis and cranial bone maneuver), all of which are under exploration. With the precision of diagnostic technologies and the targeting of therapeutic methods, future intervention strategies surrounding GS may become a significant breakthrough in overcoming the treatment impasse of AD, bringing new hope to tens of millions of AD patients worldwide.

PMID 42720212
阅读全文 →
PubMedThe Journal of dermatological treatment2026-09-10

Use of topical treatment among Swedish children with eczema during the first 18 months of life.

Af Klinteberg Maja M, Glas Bo B, Lundberg-Ulfsdotter Richard R, Domellöf Magnus M et al.

Real-world use of topical therapies in children with eczema during the first 18 months of life is insufficiently characterized. Despite guideline recommendations for regular emollients, population-based data on treatment intensity are limited. To quantify topical treatment use at 18 months, proportion reaching recommended emollient dose, and factors associated with repeated dispensing. Data from 18-month-old children (n = 5,275) in the population-based NorthPop Birth Cohort (Västerbotten, Sweden) were analyzed. Atopic dermatitis (AD) was defined using UK Working Party criteria. Eczema severity was assessed with the Patient-Oriented Eczema Measure (POEM). IgE-sensitization was analyzed using ImmunoCAP. Dispensed emollients and topical corticosteroids (TCS) during the first 18 months of life were retrieved from the Swedish Prescribed Drug Register. AD prevalence was 11.6%, higher in boys than girls (12.6% vs 10.5%, p = 0.037). Only 15.1% of children with AD reached recommended emollient dose (≥100 grams/week) (mean 43.5 g/week). Repeated emollient dispensing occurred in 42.5% (≥2 dispensings) and 14.6% had ≥5 dispensings; 60.8% were dispensed TCS. Male sex and IgE-sensitization, but not eczema severity, were associated with repeated dispensing of emollients and TCS. In this population-based cohort, topical treatment for early AD was below guideline recommendations, highlighting the importance of caregiver education and structured follow-up.

PMID 42720189
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多AD-201